Divis Laboratories Ltd News

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

JB Chem, Divis Labs among top stock recommendations by Vinay Rajani

Vinay Rajani of HDFC Securities says Divis Labs share price has broken out from the box pattern on the daily chart with the primary trend of the stock staying bullish

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

10 stocks with maximum upside this Diwali; Don't miss the market fireworks!

Leading the list is GNG Electronics (Target: ₹482 | Upside: 52%), named by Nirmal Bang, which expects robust growth as the company benefits from the govt's 'Make in India' thrust on electronics mfg.

Divis Labs rallies 13% in 1 week; What's driving pharma stock?

Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details